• +1-646-491-9876
    • +91-20-67278686

    Search

    Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2017

    Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2017

    • Report Code ID: RW0001689386
    • Category Healthcare
    • No. of Pages 189
    • Publication Month Feb-17
    • Publisher Name Global Markets Direct
    Report Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2017, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape.

    Scleroderma is a group of rare diseases that involve the hardening and tightening of the skin and connective tissues. Symptoms include muscle pains, joint pain and swelling, ulcers occurring on fingertips, bloating of the tummy and diarrhea or constipation. Treatment includes antibiotic, pain relievers and immunosuppressant.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Systemic Sclerosis (Scleroderma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 5, 12, 4, 22 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 4 molecules, respectively.

    Systemic Sclerosis (Scleroderma) (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Report Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Systemic Sclerosis (Scleroderma) (Immunology).
    - The pipeline guide reviews pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Systemic Sclerosis (Scleroderma) (Immunology) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Systemic Sclerosis (Scleroderma) (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Systemic Sclerosis (Scleroderma) (Immunology)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Systemic Sclerosis (Scleroderma) (Immunology).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Systemic Sclerosis (Scleroderma) (Immunology) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents 2
    List of Tables 4
    List of Figures 5
    Introduction 7
    Publisher Report Coverage 7
    Systemic Sclerosis (Scleroderma) - Overview 8
    Systemic Sclerosis (Scleroderma) - Therapeutics Development 9
    Pipeline Overview 9
    Pipeline by Companies 10
    Pipeline by Universities/Institutes 14
    Products under Development by Companies 15
    Products under Development by Universities/Institutes 18
    Systemic Sclerosis (Scleroderma) - Therapeutics Assessment 19
    Assessment by Target 19
    Assessment by Mechanism of Action 23
    Assessment by Route of Administration 27
    Assessment by Molecule Type 29
    Systemic Sclerosis (Scleroderma) - Companies Involved in Therapeutics Development 31
    Allergan Plc 31
    AnaMar AB 31
    Angion Biomedica Corp 32
    arGentis Pharmaceuticals LLC 32
    Bayer AG 33
    Biogen Inc 33
    BiOrion Technologies BV 34
    BLR Bio LLC 34
    Boehringer Ingelheim GmbH 35
    Bristol-Myers Squibb Company 35
    Covis Pharmaceuticals Inc 36
    CSL Ltd 36
    Cumberland Pharmaceuticals Inc 37
    F. Hoffmann-La Roche Ltd 37
    Fibrocell Science Inc 38
    GenKyoTex SA 38
    Gilead Sciences Inc 39
    GlaxoSmithKline Plc 39
    iBio Inc 40
    Inventiva 40
    Kadmon Corp LLC 41
    MedImmune LLC 41
    miRagen Therapeutics Inc 42
    Patagonia Pharmaceuticals LLC 42
    PDX Pharmaceuticals LLC 43
    Peptinov SAS 43
    ProMetic Life Sciences Inc 44
    Ribomic Inc 44
    Samumed LLC 45
    Sanofi 45
    Stemline Therapeutics Inc 46
    viDA Therapeutics Inc 46
    VivaCell Biotechnology Espana SL 47
    Systemic Sclerosis (Scleroderma) - Drug Profiles 48
    abatacept - Drug Profile 48
    acALY-18 - Drug Profile 55
    ambrisentan - Drug Profile 56
    ANG-3070 - Drug Profile 58
    ARG-201 - Drug Profile 59
    belimumab - Drug Profile 61
    BLR-200 - Drug Profile 68
    BOT-191 - Drug Profile 69
    C-1889 - Drug Profile 70
    C-82 - Drug Profile 72
    CM-101 - Drug Profile 73
    dimethyl fumarate DR - Drug Profile 74
    factor XIII (human) - Drug Profile 79
    FCX-013 - Drug Profile 80
    GKT-831 - Drug Profile 81
    GSK-2330811 - Drug Profile 84
    IBIOCFB-03 - Drug Profile 85
    ifetroban sodium - Drug Profile 87
    IVA-337 - Drug Profile 89
    JBT-101 - Drug Profile 91
    KD-025 - Drug Profile 97
    M-10 - Drug Profile 102
    MEDI-7734 - Drug Profile 103
    miRNA-29 - Drug Profile 104
    Monoclonal Antibodies to Antagonize IL-3RA for Autoimmune Disorders - Drug Profile 105
    MRG-201 - Drug Profile 106
    nintedanib - Drug Profile 108
    nitroglycerin - Drug Profile 119
    onabotulinumtoxinA - Drug Profile 121
    PAT-048 - Drug Profile 126
    PATS-03 - Drug Profile 127
    PBI-4050 - Drug Profile 128
    PDX-002 - Drug Profile 135
    PPV-06 - Drug Profile 136
    RBM-006 - Drug Profile 137
    riociguat - Drug Profile 138
    rituximab biosimilar - Drug Profile 144
    RP-182 - Drug Profile 145
    SAR-100842 - Drug Profile 146
    SAR-156597 - Drug Profile 147
    SAR-317461 - Drug Profile 148
    SM-04755 - Drug Profile 149
    Small Molecule to Inhibit NFkB for Autoimmune Disorders, Melanoma and Inflammation - Drug Profile 150
    Small Molecules to Antagonize 5-HT2B for Fibrosis - Drug Profile 151
    Synthetic Peptides to Inhibit TCR for Autoimmune Disorders and Dermatitis - Drug Profile 152
    terguride - Drug Profile 153
    tocilizumab - Drug Profile 154
    TRX-101 - Drug Profile 164
    VCE-0048 - Drug Profile 165
    VEDA-1209 - Drug Profile 166
    VTI-1000 Series - Drug Profile 167
    Wnt-001 - Drug Profile 168
    Systemic Sclerosis (Scleroderma) - Dormant Projects 169
    Systemic Sclerosis (Scleroderma) - Discontinued Products 171
    Systemic Sclerosis (Scleroderma) - Product Development Milestones 172
    Featured News & Press Releases 172
    Appendix 185
    Methodology 185
    Coverage 185
    Secondary Research 185
    Primary Research 185
    Expert Panel Validation 185
    Contact Us 185
    Disclaimer 186

    List of Tables

    Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Number of Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Number of Products under Development by Universities/Institutes, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1), H1 2017
    Products under Development by Companies, H1 2017 (Contd..2), H1 2017
    Products under Development by Universities/Institutes, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Target, H1 2017 (Contd..2), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..2), H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Allergan Plc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by AnaMar AB, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Angion Biomedica Corp, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by arGentis Pharmaceuticals LLC, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Bayer AG, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Biogen Inc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by BiOrion Technologies BV, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by BLR Bio LLC, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Boehringer Ingelheim GmbH, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Bristol-Myers Squibb Company, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Covis Pharmaceuticals Inc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by CSL Ltd, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Cumberland Pharmaceuticals Inc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by F. Hoffmann-La Roche Ltd, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Fibrocell Science Inc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by GenKyoTex SA, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Gilead Sciences Inc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by GlaxoSmithKline Plc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by iBio Inc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Inventiva, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Kadmon Corp LLC, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by MedImmune LLC, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by miRagen Therapeutics Inc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Patagonia Pharmaceuticals LLC, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by PDX Pharmaceuticals LLC, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Peptinov SAS, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by ProMetic Life Sciences Inc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Ribomic Inc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Samumed LLC, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Sanofi, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by Stemline Therapeutics Inc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by viDA Therapeutics Inc, H1 2017
    Systemic Sclerosis (Scleroderma) - Pipeline by VivaCell Biotechnology Espana SL, H1 2017
    Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2017
    Systemic Sclerosis (Scleroderma) - Dormant Projects, H1 2017 (Contd..1), H1 2017
    Systemic Sclerosis (Scleroderma) - Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development for Systemic Sclerosis (Scleroderma), H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Top 10 Targets, H1 2017
    Number of Products by Stage and Top 10 Targets, H1 2017
    Number of Products by Top 10 Mechanism of Actions, H1 2017
    Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
    Number of Products by Routes of Administration, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Allergan Plc
    AnaMar AB
    Angion Biomedica Corp
    arGentis Pharmaceuticals LLC
    Bayer AG
    Biogen Inc
    BiOrion Technologies BV
    BLR Bio LLC
    Boehringer Ingelheim GmbH
    Bristol-Myers Squibb Company
    Covis Pharmaceuticals Inc
    CSL Ltd
    Cumberland Pharmaceuticals Inc
    F. Hoffmann-La Roche Ltd
    Fibrocell Science Inc
    GenKyoTex SA
    Gilead Sciences Inc
    GlaxoSmithKline Plc
    iBio Inc
    Inventiva
    Kadmon Corp LLC
    MedImmune LLC
    miRagen Therapeutics Inc
    Patagonia Pharmaceuticals LLC
    PDX Pharmaceuticals LLC
    Peptinov SAS
    ProMetic Life Sciences Inc
    Ribomic Inc
    Samumed LLC
    Sanofi
    Stemline Therapeutics Inc
    viDA Therapeutics Inc
    VivaCell Biotechnology Espana SL

    Request for Sample

    Report Url http://www.reportsweb.com//systemic-sclerosis-scleroderma-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url http://www.reportsweb.com//systemic-sclerosis-scleroderma-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url http://www.reportsweb.com//systemic-sclerosis-scleroderma-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments